I was a shareholder of this company for many, many years and I don't understand all the dissatisfaction targetted at Gary Phillips. Arix became a major shareholder after PXS did the deal with Boehringer, which I will add, was a very good deal for an Aussie biotech. Unfortunately the liver disease is a hard one to crack, and many companies have lost billions on failed trials.
Ann: R&D Showcase Presentations Webinar 2, page-4
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.2¢ |
Change
0.002(5.00%) |
Mkt cap ! $57.67M | |||
| Open | High | Low | Value | Volume |
| 4.0¢ | 4.3¢ | 4.0¢ | $48.01K | 1.160M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1025000 | 3.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.2¢ | 461843 | 2 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| SNT (ASX) Chart |